Drug intelligence / Profile preview

finasteride

Development stage
Approved
Lead developer
Merck
Modality
Small Molecules
Administration
Oral
01

Overview

Finasteride is a synthetic 4-azasteroid and a selective inhibitor of the type II and III isoforms of the enzyme 5α-reductase. By inhibiting this enzyme in tissues such as the prostate gland and hair follicles (but not significantly in other tissues), it blocks the conversion of testosterone to dihydrotestosterone (DHT), a potent androgen responsible for prostate growth and male pattern hair loss. This results in reduced DHT levels by about 65–70% systemically and up to 80–90% within the prostate gland. Clinically approved indications include benign prostatic hyperplasia (BPH) at a dose of 5 mg daily (marketed as Proscar) and male pattern hair loss at a dose of 1 mg daily (marketed as Propecia). The drug was originally developed by Merck[1][2][5][6][7].

Brand names
PropeciaProscarAppeciaFinaloFinaraFinastFinasterid AlternovaFinasterid IVAXFinaxFincarFinpeciaFinprosHyplafinPenesterPrezepaProsterideTectum
Other names
finasteride controlled release injectionfinasteride loaded microspherefinasteride long acting injection formulationfinasteride subcutaneous injectionfinasteride sustained release injection
02

Targets

SRD5A3 (Steroid 5α-reductase 3)SRD5A2 (Steroid 5-alpha-reductase type II)

Beyond the preview

Go deeper on finasteride.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on finasteride.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call